戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  complex with palonosetron, ondansetron, and alosetron.
2 atient with IBS who was briefly treated with alosetron.
3 e blocked by the 5-HT(3) receptor antagonist alosetron (2 x 10(-7) M), whereas responses to 5-HT were
4 with the selective 5-HT3 receptor antagonist alosetron (30 microg kg-1, i.v.), did not affect the rap
5           Treatment with antidepressants and alosetron (a 5HT3 antagonist) has shown the most promise
6                     Novel approaches include alosetron; a 5-HT(3) antagonist, tegaserod, a partial 5-
7       The 5-HT3 receptor (5-HT3R) antagonist Alosetron (Alos) reduces the symptoms of female patients
8                                              Alosetron also significantly decreased urgency and stool
9              324 patients were assigned 1 mg alosetron and 323 placebo orally twice daily for 12 week
10 on occurred in 30% and 3% of patients in the alosetron and placebo groups, respectively.
11 e development of serotonergic agents such as alosetron and tegaserod.
12           A potent 5-HT3 antagonist, such as alosetron, can prevent both of these effects and is ther
13                                              Alosetron continues to be used under restricted availabi
14  women) with D-IBS received 1 mg twice a day alosetron for 6 weeks; colonic transit was measured by s
15                  79 (24%) of patients in the alosetron group and 53 (16%) in the placebo group droppe
16  a greater occurrence of constipation in the alosetron group.
17 olonic transit in response to treatment with alosetron in D-IBS.
18 side effects have been noted with the use of alosetron including severe constipation, fecal impaction
19 r phases of evoked afferent discharge, while alosetron inhibited basal afferent nerve activity.
20                                              Alosetron is a potent and selective serotonin antagonist
21 sea associated with cancer chemotherapy, and alosetron is employed in the treatment of IBS with diarr
22 he following agents: eluxadoline, rifaximin, alosetron, loperamide, tricyclic antidepressants, select
23  recommendations for eluxadoline, rifaximin, alosetron, (moderate certainty), loperamide (very low ce
24                      A greater proportion of alosetron-treated patients than placebo-treated patients
25          Symptoms correlated temporally with alosetron use, and symptoms abated with discontinuation
26                                              Alosetron was well tolerated and clinically effective in